or UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Washington, D.C. 20549 For the transition period from ______ to ______ FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 Commission file number 1-11353 LABCORP HOLDINGS INC. Indicate by check mark whether the registrant has submitted electronically every Interactive Data F ...

For the quarter ended March 2025, Labcorp (LH) reported revenue of $3.35 billion, up 5.3% over the same period last year. EPS came in at $3.84, compared to $3.68 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $3.41 billion, representing a surprise of -2.04%. The company delivered an EPS surprise of +2.95%, with the consensus EPS estimate being $3.73.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compa ...

Labcorp Holdings (LH) reported adjusted earnings per share (EPS) of $3.84 in the first quarter of 2025. The figure rose 4.3% from the year-ago reported level.The adjusted figure excludes the impacts of certain amortization expenses and restructuring charges, among others. The bottom line beat the Zacks Consensus Estimate by 2.9%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)On a GAAP basis, EPS in the first quarter was $2.52 compared with $2.69 in the year-ago period.LH Q1 Revenu ...

Labcorp shares have added about 0.1% since the beginning of the year versus the S&P 500's decline of -6%. Labcorp (LH) came out with quarterly earnings of $3.84 per share, beating the Zacks Consensus Estimate of $3.73 per share. This compares to earnings of $3.68 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of 2.95%. A quarter ago, it was expected that this medical laboratory operator would post earnings of $3.40 per share w ...

Labcorp Holdings (LH) Q1 2025 Earnings Call April 29, 2025 09:00 AM ET Company Participants Christin O'donnell - VP - Investor RelationsAdam Schechter - President, CEO & ChairmanJulia Wang - EVP & CFOLisa Gill - Managing DirectorKevin Caliendo - Managing DirectorMichael Ryskin - Managing DirectorPatrick Donnelly - Managing Director Conference Call Participants Michael Cherny - Senior Managing Director & Senior Research AnalystAnn Hynes - Senior Healthcare Services Equity Analyst & Managing DirectorErin Wrig ...

FOR IMMEDIATE RELEASE Media Investors Neil Hirsch Christin Odonnell Media@labcorp.com Investor@labcorp.com Labcorp Announces 2025 First Quarter Results Updates Full-Year Guidance BURLINGTON, N.C., April 29, 2025 – Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced results for the first quarter ended March 31, 2025 and updated full-year guidance. "Labcorp delivered solid performance in the first quarter of 2025," said Adam Schechter, chairman and CEO of L ...

Updates Full-Year Guidance Results from Operations for first quarter 2025 versus first quarter last year: Revenue: $3.35 billion versus $3.18 billion Diluted EPS: $2.52 versus $2.69 Adjusted EPS: $3.84 versus $3.68 Reaffirmed Revenue and Free Cash Flow guidance, raised midpoint of adjusted EPS: Revenue guidance of 6.7% to 8.0% Adjusted EPS range of $15.70 to $16.40; midpoint raised $0.05 Free Cash Flow of $1.10 billion to $1.25 billion Providing broader access to comprehensive testing and laboratory ser ...

Labcorp Holdings Inc. (LH) , or Labcorp, is slated to report its first-quarter 2025 results on April 29, before the opening bell.The renowned laboratory service provider reported adjusted earnings of $3.45 in the last reported quarter, topping the Zacks Consensus Estimate by 1.47%. Labcorp surpassed estimates in each of the trailing four quarters, the average surprise being 3.16%. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.)LH’s Q1 EstimatesThe Zacks Consensus Estimate for Labco ...

Core Insights - Labcorp Holdings Inc. is focusing on specialty testing areas such as oncology, women's health, autoimmune disease, and neurology to drive growth in upcoming quarters [1] - The company has a solid pipeline of potential acquisitions that align with its financial strategy and will enhance organic growth [1] - Macroeconomic issues and currency fluctuations pose challenges to Labcorp's operations [1] Financial Performance - Labcorp's stock has increased by 4.9% over the past year, contrasting with a 9.2% decline in the industry and a 1.4% decline in the S&P 500 [2] - The company has a market capitalization of $18.70 billion and an earnings yield of 7.2%, outperforming the industry's 6.3% yield [2] - Labcorp delivered an average earnings surprise of 3.2% over the trailing four quarters [2] Growth Drivers - In 2024, Labcorp enhanced its testing capabilities for neurodegenerative diseases with two new blood-based biomarkers [3] - The company expanded its oncology offerings with the Plasma Detect assay, currently in 12 global trials [3] - The Precision Oncology portfolio has seen new strategic service offerings, including FDA-approved diagnostics for gastric cancer and multiple sclerosis monitoring [4] Strategic Acquisitions - Labcorp invested $839 million in acquisitions in 2024 to strengthen its partnerships with hospitals and laboratories [5] - The company acquired assets from Lab Works and Ballad Health to enhance testing services in Alabama and the Appalachian region [5] - In December, Labcorp agreed to acquire assets from MAWD Pathology Group and introduced a new H5 bird flu molecular test in collaboration with the CDC [6] Business Segment Performance - The Biopharma Laboratory Services segment is a key growth driver, with central laboratories showing a 10% revenue increase in Q4 2024 [10] - The Early Development business also demonstrated a 12% year-over-year revenue growth [10] - Labcorp expanded its global molecular bioanalytical capacity with new facilities in Indiana and China [11] Challenges - Labcorp's operations are sensitive to macroeconomic conditions, which have reduced demand for diagnostic testing and drug development services [12] - The company faces currency headwinds due to its significant international exposure, with expected adverse impacts on revenues in 2025 [13] Earnings Estimates - The Zacks Consensus Estimate for Labcorp's 2025 earnings per share is $16.01, with revenues projected at $13.93 billion, indicating a 7.1% improvement from 2024 [14]

Labcorp's pTau-217/Beta Amyloid 42 Ratio blood test meets the performance criteria to confirm amyloid pathology consistent with Alzheimer's diseaseBURLINGTON, N.C., April 2, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide launch of its pTau-217/Beta Amyloid 42 Ratio, a powerful new blood-based biomarker test to aid in the diagnosis of Alzheimer's disease. The new test further expands Labcorp's leading blood-based bi ...